TG Therapeutics Inc (TGTX)

7.88
0.10 1.30
NASDAQ : Health Care
Prev Close 7.98
Open 7.98
Day Low/High 7.77 / 8.19
52 Wk Low/High 5.61 / 18.60
Volume 198.39K
Avg Volume 328.20K
Exchange NASDAQ
Shares Outstanding 54.46M
Market Cap 419.32M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Biotechs to Watch Ahead of the Election

2 Biotechs to Watch Ahead of the Election

These 2 small-caps have strong pipelines and are becoming analyst darlings.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.

TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results And Business Update

TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results And Business Update

Investor Conference Call to be Held Today, Monday, August 8, 2016 at 8:30am ET

TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2016 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Second Quarter 2016 Financial Results And Business Update

Investor Conference Call to be held Monday, August 8, 2016 at 8:30am ET

Relative Strength Alert For TG Therapeutics

Relative Strength Alert For TG Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of TGTX February 2017 Options Trading

First Week of TGTX February 2017 Options Trading

Investors in TG Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TG Therapeutics, Inc. Announces Data From TGR-1202 In Combination With Ibrutinib As Well As Recaps Long-Term Safety And Efficacy Data Of TGR-1202 In CLL And NHL At The 21st European Hematology Association Annual Congress

TG Therapeutics, Inc. Announces Data From TGR-1202 In Combination With Ibrutinib As Well As Recaps Long-Term Safety And Efficacy Data Of TGR-1202 In CLL And NHL At The 21st European Hematology Association Annual Congress

Combination of TGR-1202 + Ibrutinib appears well-tolerated and active in relapsed/refractory CLL patients treated with the combination

TG Therapeutics, Inc. To Present At The Jefferies 2016 Healthcare Conference

TG Therapeutics, Inc. To Present At The Jefferies 2016 Healthcare Conference

Presentation Scheduled for Friday June 10, 2016 at 10:00am ET

Weak On High Volume: TG Therapeutics (TGTX)

Weak On High Volume: TG Therapeutics (TGTX)

Trade-Ideas LLC identified TG Therapeutics (TGTX) as a weak on high relative volume candidate

TG Therapeutics, Inc. Recaps Schedule Of Clinical Data Presentations At The 52nd Annual Meeting Of The American Society Of Clinical Oncology

TG Therapeutics, Inc. Recaps Schedule Of Clinical Data Presentations At The 52nd Annual Meeting Of The American Society Of Clinical Oncology

Investor Reception to be Held on Monday June 6, 2016 at 7:00pm CT at the Peninsula Chicago Hotel with Presentations by Leading Clinical Investigators

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 21st European Hematology Association Annual Congress

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 21st European Hematology Association Annual Congress

Presentations demonstrate the safety and efficacy of TGR-1202 in combination with ublituximab as well as in combination with ibrutinib in patients with CLL and NHL

TG Therapeutics, Inc. Announces Clinical Data Presentation At The Upcoming 52nd Annual Meeting Of The American Society Of Clinical Oncology

TG Therapeutics, Inc. Announces Clinical Data Presentation At The Upcoming 52nd Annual Meeting Of The American Society Of Clinical Oncology

An integrated-analysis of the long term follow up of TGR-1202 monotherapy and in combination with TG-1101 (ublituximab) to be featured in a poster presentation and discussion session

RSI Alert: TG Therapeutics (TGTX) Now Oversold

RSI Alert: TG Therapeutics (TGTX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results And Business Update

TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results And Business Update

Investor Conference Call to be Held Today, Tuesday, May 10, 2016 at 4:30pm ET

TG Therapeutics, Inc. To Host Conference Call On First Quarter 2016 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On First Quarter 2016 Financial Results And Business Update

Investor Conference Call to be held Tuesday, May 10, 2016 at 4:30pm ET  

'Mad Money' Lightning Round: Get Ready to Buy Palo Alto Networks

'Mad Money' Lightning Round: Get Ready to Buy Palo Alto Networks

Cramer likes Constellation Brands over Boston Beer and admits he's been wrong before on Fitbit.

Jim Cramer's 'Mad Money' Recap: Stay Positive, Stay Focused, Ignore Apple

Jim Cramer's 'Mad Money' Recap: Stay Positive, Stay Focused, Ignore Apple

You could focus on Apple's disappointing quarter but just about everything else outside of tech stocks is heading higher, Cramer says.

Commit To Purchase TG Therapeutics At $7.50, Earn 16.2% Annualized Using Options

Commit To Purchase TG Therapeutics At $7.50, Earn 16.2% Annualized Using Options

Investors considering a purchase of TG Therapeutics Inc stock, but cautious about paying the going market price of $10.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 70 cents.

Insider Trading Alert - BLOX, ILMN And TGTX Traded By Insiders

Insider Trading Alert - BLOX, ILMN And TGTX Traded By Insiders

Stocks with insider trader activity include BLOX, ILMN and TGTX